Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies

Date: October 22, 2010
Pages: 106
Price:
US$ 961.00
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C7F7DEE19A1EN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies
Product description

The present Competitive Intelligence Report about Biosimilar and Biobetter/Biosuperior Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies directed against CD20, Her2, VEGF, TNF, EGF-R, RSV and GPIIb/IIIa as of October 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of therapeutic antibodies are beginning to expire over the next few years. With 2009 combined sales of US$ 35.5 bln for only six pharmacologic classes, therapeutic antibodies are quite an attractive field for companies to embark on with biosimilar or biobetter/biosuperior antibodies. Apart from the economic attractiveness, it is also the validated target of therapeutic antibodies which attracts technology companies to create and develop improved versions of established therapeutic antibodies against CD20, Her2, VEGF, TNF, EGF-R and TNF. Further players in this field are Big Pharma companies trying to defend their market with next generation molecules, as well as biopharmaceutical companies from “off-patent” countries with the intention to offer valuable therapeutics at locally affordable prices.

The report includes a compilation of currently active projects in research and development of biosimilar and biobetter/biosuperior antibodies against CD20, Her2, VEGF, TNF, RSV and GPIIb/IIIa. In addition, the report lists company-specific R&D pipelines of biosimilar and biobetter/biosuperior antibodies. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
Index

1) Anti-CD20 Antibodies
1a) Market Size 2009 Anti-CD20 Antibody
1b) Biosimilar anti-CD20 Antibodies
1c) Biobetter/Biosuperior anti-CD20 Antibodies

2) Anti-Her2 Antibodies
2a) Market Size anti-Her2 Antibody
2b) Biosimilar anti-Her2 Antibodies
2c) Biobetter/Biosuperior anti-Her2 Antibodies

3a) Anti-VEGF Antibodies
3a) Market Size Anti-VEGF Antibodies
3b) Biosimilar anti-VEGF Antibodies
3c) Biobetter/Biosuperior anti-VEGF Antibodies

4) Anti-TNF Antibodies
4a) Market Size anti-TNF Antibodies
4b) Biosimilar anti-TNF Antibodies
4c) Biobetter/Biosuperior anti-TNF Antibodies

5) Anti-EGF-R Antibodies
5a) Market Size anti-EGF-R Antibodies
5b) Biosimilar anti-EGF-R Antibodies
5c) Biobetter/Biosuperior anti-EGF-R Antibodies

6) Anti-RSV Antibodies
5a) Market Size anti-RSV Antibodies
5b) Biosimilar anti-RSV Antibodies
5c) Biobetter/Biosuperior anti-RSV Antibodies

6) Anti-GPIIB/IIIA Antibodies
5a) Market Size anti-GIIb/IIIa Antibodies
5b) Biosimilar anti-GPIIb/IIIa Antibodies

Corporate Biosimilar and Biobetter/Biosuperior Antibody R&D Pipelines

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Skip to top


Ask Your Question

Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: